MYGN - Myriad Genetics Inc logo

Myriad Genetics Inc

MYGN

Myriad Genetics develops and offers molecular diagnostic tests in oncology, women's health, and pharmacogenomics. Key products include hereditary cancer tests, prenatal screening, and tests for mental health medication selection, serving healthcare providers.

โš•๏ธ Healthcare NASDAQ Listed 1995 $ USD
$1,000 invested 30 years ago โ†’$779today

Score Overview

1 Year
Score
Net Growth69.23%
Net TrendGrew
Net Income Consistencyโ€”
Rev Growth-2.17%
Rev TrendShrank
Revenue Consistencyโ€”
5 Years
Score2.9
Net Growth-313.97%
Net Trend40%
Net Income Consistencyโ€”
Rev Growth16.80%
Rev Trend40%
Revenue Consistencyโ€”
10 Years
Score
Net Growth-189.86%
Net Trend40%
Net Income Consistency
Rev Growth7.00%
Rev Trend60%
Revenue Consistency
20 Years
Score4.0
Net Growth-194.85%
Net Trend60%
Net Income Consistency
Rev Growth7x
Rev Trend70%
Revenue Consistency
30 Years
Score
Net Growth-17x
Net Trend53%
Net Income Consistency
Rev Growth122x
Rev Trend77%
Revenue Consistency
All Time
Score
Net Growth-17x
Net Trend53%
Net Income Consistency
Rev Growth122x
Rev Trend77%
Revenue Consistency

Explore the 2021 public Archive ranking โ†’

Where Myriad Genetics Inc has ranked, year by year

Measure
Fundamentals Window

Showing 10 years ranking history by HDB Score.

Has not reached the top 50 on HDB Score in any year we have ranked.

  • MYGN

2007: 83.2% ยท 2021: 63.8% ยท free through 2021 ยท longest runs

Net Income x Stock Price

Historical Returns

Historical Returns
PeriodPriceReturn
Last Price2026-09-28
$ 4.24โ€”
1 Year2025-09-26
$ 7.70-44.94%
5 Years2021-09-28
$ 31.64-86.60%
10 Years2016-09-28
$ 21.58-80.35%
20 Years2006-09-28
$ 10.60-60.00%
30 Years1996-09-27
$ 5.45-22.15%

Prices are split & dividend adjusted. All values are reported in USD.

Fundamental Data

Reported in USD

Year
TTM$ 806M-$ 112M$ 115M
2025$ 824M-$ 365M$ 149M
2024$ 837M-$ 127M$ 102M
2023$ 753M-$ 263M$ 140M
2022$ 678M-$ 112M$ 114M
2021$ 690M-$ 27M$ 339M
2020$ 557M-$ 223M$ 150M
2019$ 851M$ 4M$ 136M
2018$ 772M$ 131M$ 180M
2017$ 771M$ 21M$ 150M
2016$ 753M$ 125M$ 159M
2015$ 723M$ 80M$ 144M
2014$ 778M$ 176M$ 270M
2013$ 613M$ 147M$ 531M
2012$ 496M$ 112M$ 454M
2011$ 402M$ 100M$ 346M
2010$ 362M$ 152M$ 403M
2009$ 326M$ 84M$ 316M
2008$ 333M$ 47M$ 328M
2007$ 157M-$ 34M$ 308M
2006$ 114M-$ 38M$ 227M
2005$ 82M-$ 39M$ 113M
2004$ 56M-$ 40M$ 115M
2003$ 64M-$ 24M$ 72M
2002$ 53M-$ 13M$ 73M
2001$ 45M-$ 7M$ 127M
2000$ 34M-$ 8M$ 80M
1999$ 25M-$ 10M$ 9M
1998$ 23M-$ 9M$ 14M
1997$ 15M-$ 9M$ 15M
IPO1995$ 6M-$ 5M$ 13M
MYGN - Myriad Genetics Inc logo

Myriad Genetics Inc fundamental performance

Between 2005 and 2025, revenue grew from $ 82M to $ 824M and net income went from -$ 39M to -$ 365M. Revenue increased in 14 of those 20 years; net income in 12.

Across Myriad Genetics Inc's full reported history, from 1995 to 2025, revenue grew from $ 6M to $ 824M and net income went from -$ 5M to -$ 365M. Revenue increased in 77% of the years measured; net income in 53%.

Myriad Genetics Inc currently holds a 20-year HDB Score of 4.0 out of 10. How the HDB Score is calculated.

Membership

Continue MYGNโ€™s history

The public Archive runs through 2021. Membership adds recent and current rankings.

  • Recent and current rankings across 3,816 companies
  • Compare companies with the latest data
  • Track your research shortlist in a portfolio

$99 / year

$149/year ยท Founding price

Continue with Membership

30-day money-back guarantee.

Explore other companies